FLT-PET for Early Detection of Relapse in Patients With Irradiated Lung Cancer
NCT ID: NCT02995889
Last Updated: 2022-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
64 participants
INTERVENTIONAL
2014-11-30
2020-02-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
FLT-PET/DW-MRI for Detection of Brain Metastases and Early Therapy Evaluation in Patients With Small Cell Lung Cancer
NCT02995902
Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy
NCT02139150
PET-DECT for Staging and Imaged Based Radiotherapy Planning in Lung Cancer
NCT03146117
Pilot Study of 18F-FLT PET
NCT00585741
MPDL3280A-imaging-IST-UMCG
NCT02453984
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FLT-PET
FLT-PET
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FLT-PET
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* radiotherapy of lung cancer ended within the last 24 months
* radiotherapy might be normofractionated or stereotactic
* current suspicion of relapse
* written and oral consent
Exclusion Criteria
* pregnancy or lactation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tine Nøhr Christensen
MD, research fellow
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andreas Kjær, MD phD MDSci
Role: STUDY_CHAIR
Dept of Clinical Physiology, Nuclear medicine and PET, Rigshospitalet, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dept. of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet
Copenhagen, , Denmark
Dept. Respiratory Medicine, Bispebjerg University Hospital
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Christensen TN, Langer SW, Persson G, Larsen KR, Loft A, Amtoft AG, Berthelsen AK, Johannesen HH, Keller SH, Kjaer A, Fischer BM. 18F-FLT PET/CT Adds Value to 18F-FDG PET/CT for Diagnosing Relapse After Definitive Radiotherapy in Patients with Lung Cancer: Results of a Prospective Clinical Trial. J Nucl Med. 2021 May 10;62(5):628-635. doi: 10.2967/jnumed.120.247742. Epub 2020 Oct 9.
Christensen TN, Langer SW, Persson G, Larsen KR, Amtoft AG, Keller SH, Kjaer A, Fischer BM. Impact of [18F]FDG-PET and [18F]FLT-PET-Parameters in Patients with Suspected Relapse of Irradiated Lung Cancer. Diagnostics (Basel). 2021 Feb 11;11(2):279. doi: 10.3390/diagnostics11020279.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
308_14
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.